Honduras Medical Device Legal Framework
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
The legal sources for devices in Honduras can be arranged in 4 layers: the Constitution (Articles 145 and 146, right to health protection and the regulatory duty of the State); laws and decrees (Decreto No. 7-2021, the ARSA law, and the Código de Salud); regulations (Acuerdo No. 0631-ARSA-2023, the sanitary control regulation for devices, and Acuerdo No. 0185-ARSA-2025, the technovigilance regulation); and administrative resolutions (Acuerdo No. 003-2021 and Acuerdo No. 012-2020, which set processing deadlines and service fees). The main regulation 0631-ARSA-2023 was signed in Comayagüela on 2023-12-28 and published in La Gaceta No. 36,646 of 2024-09-21; its SECOND provision sets entry into force 20 days after publication. Article 89 sets the supplementary order of application: treaties and conventions, the Health Code, the Civil Procedure Code, the General Law of Public Administration, the Administrative Procedures Law, general principles of law, and the technical provisions issued by ARSA on its own initiative.
- Treating 0631-ARSA-2023 as the only basis misses fees and deadlines: those sit in Acuerdos 012-2020 and 003-2021.
- The device regulation and the technovigilance regulation entered into force on different dates, so compliance calendars must mark two switching points.
- The main fee table of Acuerdo 012-2020 exists only as an image, so amounts are pending verification and only the pricing basis can be cited.
2. Legal basis
The four layers, with the provisions each obligation rests on, are as follows.
| Constitution | Constitución de la República | Art. 145, 146 | Recognises the right to health protection; the State regulates, monitors and controls products (cited in the legislative-basis column of 0631-ARSA-2023). |
| Law | Código de Salud | Articles 1, 4, 225, 226 and 240 | Sanitary definitions and duties of the State; Article 226 is the reference for the cap on fines for late renewal. |
| Law | Decreto No. 7-2021 | Articles 1, 7 and 12; La Gaceta No. 35,626, 2021-06-12 | Ratifies the creation of ARSA; lists 10 powers; regulations to be issued within 3 months. |
| Regulation | Acuerdo No. 0631-ARSA-2023, Reglamento para el Control Sanitario de Dispositivos Médicos y otros Dispositivos de Interés Sanitario | 93 articles in total; La Gaceta No. 36,646, 2024-09-21 | General rules for the sanitary control of devices and other devices of sanitary interest; SECOND provision, in force 20 days after publication. |
| Regulation | Acuerdo No. 0185-ARSA-2025, Reglamento de Tecnovigilancia | 29 articles in total; La Gaceta No. 36,954, 2025-09-29 | Technovigilance: event grading, reporting deadlines and semi-annual reports; Article 29, in force 20 days after publication. |
| Administrative resolution | Acuerdo No. 012-2020 | Provisions SECOND to TENTH; La Gaceta No. 35,299, 2020-06-30 | Processing deadlines and service fees for 11 categories of matters of the Devices Directorate (the main fee table is an image; amounts pending verification). |
| Administrative resolution | Acuerdo No. 003-2021 | Provision FOURTH and Tables 1 to 4; La Gaceta No. 35,552, 2021-03-23 | Establishment licences priced in fractions of the Salario Mínimo Promedio, with separate on-site and online rates; 60 working days for new licences and renewals. |
| Regulation | Acuerdo No. 0631-ARSA-2023, Reglamento para el Control Sanitario de Dispositivos Médicos y otros Dispositivos de Interés Sanitario | Article 89 | Supplementary order of application for matters not covered: international treaties, Health Code, Civil Procedure Code, General Law of Public Administration, Administrative Procedures Law, general principles of law, and ARSA technical provisions. |
3. Expert insights
Insight 1: a fixed 20-day gap separates publication from entry into force. The SECOND provision of 0631-ARSA-2023 and Article 29 of the technovigilance regulation both state that the rule enters into force 20 days after publication, but the publication dates differ: 2024-09-21 for the former and 2025-09-29 for the latter. The effect for companies is that the switching points between the old and new regimes differ: registration obligations run under the new rules from the fourth quarter of 2024, while the reporting clock for vigilance only starts under the new rules in the fourth quarter of 2025. Compliance calendars must mark the two dates separately and must not use a single day for both.
Insight 2: fees and deadlines are not in the main regulation. The 93 articles of the main regulation only settle whether an authorisation is needed, what documents it requires and how long it lasts; processing deadlines and service fees sit in Acuerdo 012-2020 (11 categories of matters of the Devices Directorate) and Acuerdo 003-2021 (establishment licences, priced in fractions of the minimum average wage, with separate on-site and online scales). The GRZAN regulatory team notes that these two resolutions apply to specific matters, not to product risk classes, so any citation must name the category of matter.
Insight 3: the main fee table of Acuerdo 012-2020 is an image with no text layer. When checking the official PDF, we found that the fee tables of provisions SECOND to TENTH are laid out as images, so the specific amounts cannot be verified from the text layer; only provision SEVENTH (special authorisation for non-governmental organisations) can be read as 5 working days and 1/9 of the minimum average wage. This volume therefore gives no specific official-fee figures and states only the verifiable pricing basis. This is the most important no-numbers decision of this series.
Insight 4: the supplementary order of Article 89 is the backstop in disputes. Where the regulation does not expressly provide, the order of application is international treaties, the Health Code, the Civil Procedure Code, the General Law of Public Administration, the Administrative Procedures Law and general principles of law, with ARSA technical provisions last. The practical value for applicants is that procedural remedies can be argued from the Administrative Procedures Law, without needing to find an answer inside internal ARSA guidance.
Insight 5: Article 93 gave ARSA a 180-day window for supporting legislation. Article 93 of the main regulation requires ARSA to issue agreements, procedures, manuals, guides and internal norms within 180 days of publication. The texts relied on in this volume are settled, but supporting detail is still landing progressively; content must be rechecked quarterly, especially the format versions of document lists, since Article 32 repeatedly requires forms established by ARSA.
4. Practical recommendations
- Build a four-layer source table for this market and tag every obligation to a specific document and article, avoiding mixed citations.
- Mark the two switching points separately on the compliance calendar: the fourth quarter of 2024 (main device regulation) and the fourth quarter of 2025 (technovigilance regulation).
- When citing fees, write only that pricing is in fractions of the minimum average wage as published by ARSA for the period, and never state specific amounts.
- In procedural disputes (deficiencies, deadlines, service of documents), search the Administrative Procedures Law and the General Law of Public Administration first, not only internal ARSA guidance.
- Recheck the Acuerdos and Reglamentos Nacionales sections of the ARSA legal library quarterly, focusing on new format versions.
- Wherever a document list mentions a form established by ARSA, confirm the current version number with the counter window before filing.
5. Verification checklist
- □ A four-layer source table exists and every obligation traces to a document and article
- □ The compliance calendar marks the 2024 and 2025 switching points separately
- □ Quotations and budget documents contain no specific official-fee figures without an official source
- □ Cited fee bases come from Acuerdo 003-2021 or 012-2020, not from the main regulation
- □ The search list for procedural disputes includes the Administrative Procedures Law and the General Law of Public Administration
- □ All ARSA-form items in document lists have had their current version number confirmed
Regulatory information verified as of 2026-10-29.
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Honduran market. Our team manages Secretariat of Health (SESAL) registration applications through the regulatory directorate, prepares Spanish-language dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us